Biotech · Private company
Olix Pharmaceuticals, Inc.
Track this companyFree. Adds Olix Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- OLX10010Phase 2 · Hypertrophic ScarClinicalTrials.gov · fetched Nov 12, 2026
- OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)Phase 1 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Evaluation of OLX10212 in Patients With Neovascular Age-related Macular DegenerationPHASE1 · COMPLETED · started Jan 4, 2023ClinicalTrials.gov NCT05643118 · fetched Nov 12, 2026
- Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular DegenerationTERMINATED · started Sep 1, 2021ClinicalTrials.gov NCT05038371 · fetched Nov 12, 2026
- Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision SurgeryPHASE2 · COMPLETED · started Aug 19, 2021ClinicalTrials.gov NCT04877756 · fetched Nov 12, 2026